Inspire Advisors LLC Raises Position in West Pharmaceutical Services, Inc. $WST

Inspire Advisors LLC raised its stake in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 48.0% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,431 shares of the medical instruments supplier’s stock after acquiring an additional 788 shares during the period. Inspire Advisors LLC’s holdings in West Pharmaceutical Services were worth $532,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in WST. Zions Bancorporation National Association UT purchased a new position in West Pharmaceutical Services during the first quarter worth about $25,000. Quarry LP purchased a new position in shares of West Pharmaceutical Services in the 1st quarter worth approximately $27,000. CVA Family Office LLC boosted its stake in shares of West Pharmaceutical Services by 573.3% in the 2nd quarter. CVA Family Office LLC now owns 202 shares of the medical instruments supplier’s stock worth $44,000 after buying an additional 172 shares during the last quarter. Cromwell Holdings LLC grew its holdings in shares of West Pharmaceutical Services by 587.5% in the second quarter. Cromwell Holdings LLC now owns 220 shares of the medical instruments supplier’s stock valued at $48,000 after acquiring an additional 188 shares in the last quarter. Finally, Brooklyn Investment Group increased its position in shares of West Pharmaceutical Services by 83.3% during the first quarter. Brooklyn Investment Group now owns 275 shares of the medical instruments supplier’s stock valued at $61,000 after acquiring an additional 125 shares during the last quarter. Institutional investors own 93.90% of the company’s stock.

West Pharmaceutical Services Stock Down 0.7%

WST stock opened at $258.31 on Thursday. The stock has a fifty day moving average of $269.12 and a 200-day moving average of $242.80. West Pharmaceutical Services, Inc. has a fifty-two week low of $187.43 and a fifty-two week high of $348.90. The company has a market capitalization of $18.58 billion, a price-to-earnings ratio of 38.27, a PEG ratio of 4.09 and a beta of 1.08. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.18 and a current ratio of 2.87.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings data on Thursday, October 23rd. The medical instruments supplier reported $1.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.67 by $0.29. The business had revenue of $804.60 million for the quarter, compared to analysts’ expectations of $788.42 million. West Pharmaceutical Services had a return on equity of 18.16% and a net margin of 16.29%.The firm’s quarterly revenue was up 7.7% compared to the same quarter last year. During the same period in the previous year, the business posted $1.85 EPS. West Pharmaceutical Services has set its FY 2025 guidance at 7.060-7.110 EPS. As a group, equities research analysts predict that West Pharmaceutical Services, Inc. will post 6.62 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. Zacks Research cut West Pharmaceutical Services from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 23rd. KeyCorp lifted their target price on West Pharmaceutical Services from $325.00 to $350.00 and gave the stock an “overweight” rating in a research note on Friday, October 24th. Redburn Partners set a $311.00 price target on shares of West Pharmaceutical Services in a research report on Monday, September 15th. UBS Group raised their price objective on shares of West Pharmaceutical Services from $320.00 to $355.00 and gave the stock a “buy” rating in a report on Friday, October 24th. Finally, Rothschild & Co Redburn assumed coverage on shares of West Pharmaceutical Services in a research report on Monday, September 15th. They issued a “buy” rating and a $311.00 price objective on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, West Pharmaceutical Services currently has a consensus rating of “Moderate Buy” and a consensus price target of $349.20.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.